Kestra Medical Technologies (KMTS) Company presentation summary

Market opportunity and clinical need

• U.S. market for wearable cardioverter defibrillators (WCDs) estimated at $10B, with $1B currently accessible and significant room for expansion driven by clinical guideline updates and improved patient adherence.

• Approximately 850,000 patients annually are eligible for WCDs, but only about 120,000 are currently protected, highlighting a large unpenetrated market.

• Sudden cardiac arrest (SCA) remains a leading cause of death, with 436,000 deaths per year in the U.S., and 73% of events occurring at home.

• The first 90 days post-diagnosis represent the highest risk period for SCA, yet many patients remain unprotected due to ICD waiting periods.

Product innovation and clinical validation

• The ASSURE WCD system offers improved comfort, actionable insights, and high patient compliance, addressing key limitations of legacy products.

• Real-world data from the ACE-PAS study (over 21,000 patients) demonstrates 100% shock conversion, exceptionally low inappropriate shock rates, and expanded clinical utility.

• Integration with the BioBeat sensor enables continuous, non-invasive blood pressure monitoring, supporting future clinical applications.

• The platform is built for extensibility, with robust IP protection and infrastructure to support new sensors and data streams.

Commercial execution and financial performance

• Achieved broad insurance coverage, now reaching 290M+ covered lives (about 90% of the U.S. insured population), supported by stable Medicare reimbursement.

• Rapid expansion of the commercial team and sales territories, targeting high-prescribing hospitals and clinics for efficient market penetration.

• Rental and re-use business model for WCDs drives attractive unit economics, with eight consecutive quarters of gross margin expansion, reaching over 50% in 2Q26.

• Fiscal year 2026 revenue guidance projects $93M, reflecting strong year-over-year growth rates and commercial momentum.